Speakers

Christopher T. Griffith
Christopher T. Griffith
Chris is a founding partner of Green, Griffith & Borg-Breen LLP.  As a seasoned IP trial lawyer with experience as lead counsel, Chris concentrates his practice on pharmaceuticals, chemicals and biotechnology.

Chris has decades of experience in Hatch-Waxman litigation, leveraging his advocacy and technical skills to help clients shape successful litigation strategies.  He has represented both patentees and defendants in actions before the U.S. District Courts and in appeals before the Court of Appeals for the Federal Circuit.

As a partner to his clients, Chris provides strategic formulation development and pre-litigation guidance concerning IP and FDA exclusivity issues affecting 505(b)(1), 505(b)(2) and ANDA drug applications.  Depending on the desired strategy, this guidance includes opinions and counseling on API and excipient selection, formulation attributes and indications, and patent validity, regardless of whether the client focus is defending against or asserting Paragraph IV or Section viii challenges.

Patent portfolio management relating to 505(b)(1) and 505(b)(2) applications, including the assessment of existing portfolios, and developing strategies for further enhancement of those portfolios, is also a significant part of his practice.

He also possesses experience in reexaminations, reissues, inter partes review and post-grant proceedings under the AIA.

Chris enjoys lecturing and teaching, most recently presenting at the 2017 Paragraph IV Disputes Symposium, and frequently lectures at the Chinese IP Resource Center at The John Marshall Law School.  He is also a former adjunct professor at the law school, where he developed and taught a Master's level course in patent law for many years.

Prior to co-founding Green Griffith in 2015, Chris was Corporate Secretary of Leydig, Voit & Mayer Ltd. and served on its Board of Directors.
  
 

  Media Partner